Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer - A Randomized Clinical Trial

In this study (n=88; median one (range 0-2) prior lines of chemotherapy and 2 (0-5) lines of hormonal therapy), the addition of pembrolizumab to eribulin did not improve PFS (primary endpoint; 4.1 vs 4.2 with eribulin alone; HR 0.80; 95% CI 0.50-1.26; P=0.33).


JAMA Oncology